Email this page

Print this page

Report

Inhibition of intracranial glioma growth by endometrial regenerative cells

Xiaodi Han, Xiaolong Meng, Zhenglian Yin, Andrea Rogers, Jie Zhong, Paul Rillema, James A. Jackson, Thomas E. Ichim, Boris Minev, Ewa Carrier, Amit N. Patel, Michael P. Murphy, Wei-Ping Min and Neil H. Riordan

 Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.

Animal studies have demonstrated that selective tropism of mesenchymal stem cells (MSC) for glioma may be used as a means of selective delivery of cytotoxic payloads.  Endometrial Regenerative Cells (ERC) are a population of mesenchymal-like cells which possesse pluripotent differentiation capacity and is characterized by unique surface markers and growth factor production.  In this study we sought to determine whether unmanipulated ERC would alter the growth of glioma using the aggressive C6/LacZ7 (C6) into Sprague Dawley rat model.  ERC administration by intravenous (i.v.) or intratumoral (i.t.) showed significant inhibition of glioma: volume reduction of 49% after i.v. treatment (p<0.05), and about 46% i.t. treatment (p<0.05). Tumor reduction was associated with inhibition of angiogenesis and reduced numbers of CD133 positive cells in the incranial tumor.  Despite the angiogenic potential of ERC in the hindlimb ischemia model, these data support a paradoxical tumor inhibitory activity of ERC.  Further studies are needed to determine the qualitative differences between physiological angiogenesis, which seems to be supported by ERC and tumor angiogenesis which appeared to be inhibited.

Authors

Xiaodi Han

Bio-Communications Research Institute; Wichita, Kansas

Xiaolong Meng

Bio-Communications Research Institute; Wichita, Kansas

Zhenglian Yin

Bio-Communications Research Institute; Wichita, Kansas

Andrea Rogers

Bio-Communications Research Institute; Wichita, Kansas

Jie Zhong

Bio-Communications Research Institute; Wichita, Kansas

Paul Rillema

Wichita State University; Wichita, Kansas

James A. Jackson

Bio-Communication Research Institute; Wichita, Kansas

Thomas E. Ichim Corresponding author: Thomas.ichim@gmail.com

Medistem Inc.; San Diego, CA

Boris Minev

Moores UCSD Cancer Centre; San Diego, CA

Ewa Carrier

Moores UCSD Cancer Centre; San Diego, CA

Amit N. Patel

University of Utah; Salt Lake City, UT

Michael P. Murphy

Indiana University School of Medicine; Indianapolis, IN

Wei-Ping Min

University of Western Ontario; Ontario, Canada

Neil H. Riordan

Bio-Communications Research Institute; Wichita, Kansas

 Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.